These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 17310122)

  • 1. Amyloid beta1-40 quantification in CSF: comparison between chromatographic and immunochemical methods.
    Simonsen AH; Hansson SF; Ruetschi U; McGuire J; Podust VN; Davies HA; Mehta P; Waldemar G; Zetterberg H; Andreasen N; Wallin A; Blennow K
    Dement Geriatr Cogn Disord; 2007; 23(4):246-50. PubMed ID: 17310122
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Amyloid beta peptides in cerebrospinal fluid as profiled with surface enhanced laser desorption/ionization time-of-flight mass spectrometry: evidence of novel biomarkers in Alzheimer's disease.
    Lewczuk P; Esselmann H; Groemer TW; Bibl M; Maler JM; Steinacker P; Otto M; Kornhuber J; Wiltfang J
    Biol Psychiatry; 2004 Mar; 55(5):524-30. PubMed ID: 15023581
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantitative analysis of amyloid-beta peptides in cerebrospinal fluid using immunoprecipitation and MALDI-Tof mass spectrometry.
    Gelfanova V; Higgs RE; Dean RA; Holtzman DM; Farlow MR; Siemers ER; Boodhoo A; Qian YW; He X; Jin Z; Fisher DL; Cox KL; Hale JE
    Brief Funct Genomic Proteomic; 2007 Jun; 6(2):149-58. PubMed ID: 17584762
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantitative analysis of amyloid beta peptides in cerebrospinal fluid of Alzheimer's disease patients by immunoaffinity purification and stable isotope dilution liquid chromatography/negative electrospray ionization tandem mass spectrometry.
    Oe T; Ackermann BL; Inoue K; Berna MJ; Garner CO; Gelfanova V; Dean RA; Siemers ER; Holtzman DM; Farlow MR; Blair IA
    Rapid Commun Mass Spectrom; 2006; 20(24):3723-35. PubMed ID: 17117458
    [TBL] [Abstract][Full Text] [Related]  

  • 5. No correlation between time-linked plasma and CSF Abeta levels.
    Le Bastard N; Aerts L; Leurs J; Blomme W; De Deyn PP; Engelborghs S
    Neurochem Int; 2009 Dec; 55(8):820-5. PubMed ID: 19695299
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans.
    Fagan AM; Mintun MA; Mach RH; Lee SY; Dence CS; Shah AR; LaRossa GN; Spinner ML; Klunk WE; Mathis CA; DeKosky ST; Morris JC; Holtzman DM
    Ann Neurol; 2006 Mar; 59(3):512-9. PubMed ID: 16372280
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of novel APP/Abeta isoforms in human cerebrospinal fluid.
    Portelius E; Brinkmalm G; Tran AJ; Zetterberg H; Westman-Brinkmalm A; Blennow K
    Neurodegener Dis; 2009; 6(3):87-94. PubMed ID: 19229112
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cerebrospinal fluid amyloid beta peptide patterns in Alzheimer's disease patients and nondemented controls depend on sample pretreatment: indication of carrier-mediated epitope masking of amyloid beta peptides.
    Bibl M; Esselmann H; Otto M; Lewczuk P; Cepek L; Rüther E; Kornhuber J; Wiltfang J
    Electrophoresis; 2004 Sep; 25(17):2912-8. PubMed ID: 15349929
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Amyloid beta 38, 40, and 42 species in cerebrospinal fluid: more of the same?
    Schoonenboom NS; Mulder C; Van Kamp GJ; Mehta SP; Scheltens P; Blankenstein MA; Mehta PD
    Ann Neurol; 2005 Jul; 58(1):139-42. PubMed ID: 15984010
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An Alzheimer's disease-specific beta-amyloid fragment signature in cerebrospinal fluid.
    Portelius E; Zetterberg H; Andreasson U; Brinkmalm G; Andreasen N; Wallin A; Westman-Brinkmalm A; Blennow K
    Neurosci Lett; 2006 Dec; 409(3):215-9. PubMed ID: 17049739
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prediction of Alzheimer's disease using the CSF Abeta42/Abeta40 ratio in patients with mild cognitive impairment.
    Hansson O; Zetterberg H; Buchhave P; Andreasson U; Londos E; Minthon L; Blennow K
    Dement Geriatr Cogn Disord; 2007; 23(5):316-20. PubMed ID: 17374949
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Concentrations of metals, beta-amyloid and tau-markers in cerebrospinal fluid in patients with Alzheimer's disease.
    Gerhardsson L; Blennow K; Lundh T; Londos E; Minthon L
    Dement Geriatr Cogn Disord; 2009; 28(1):88-94. PubMed ID: 19672066
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of CSF biomarkers for frontotemporal dementia using SELDI-TOF.
    Rüetschi U; Zetterberg H; Podust VN; Gottfries J; Li S; Hviid Simonsen A; McGuire J; Karlsson M; Rymo L; Davies H; Minthon L; Blennow K
    Exp Neurol; 2005 Dec; 196(2):273-81. PubMed ID: 16154129
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased cerebrospinal fluid levels of transforming growth factor-beta1 in Alzheimer's disease.
    Zetterberg H; Andreasen N; Blennow K
    Neurosci Lett; 2004 Sep; 367(2):194-6. PubMed ID: 15331151
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oligomerization partially explains the lowering of Abeta42 in Alzheimer's disease cerebrospinal fluid.
    Englund H; Degerman Gunnarsson M; Brundin RM; Hedlund M; Kilander L; Lannfelt L; Pettersson FE
    Neurodegener Dis; 2009; 6(4):139-47. PubMed ID: 19521063
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain.
    Tapiola T; Alafuzoff I; Herukka SK; Parkkinen L; Hartikainen P; Soininen H; Pirttilä T
    Arch Neurol; 2009 Mar; 66(3):382-9. PubMed ID: 19273758
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel T719P AbetaPP mutation unbalances the relative proportion of amyloid-beta peptides.
    Ghidoni R; Albertini V; Squitti R; Paterlini A; Bruno A; Bernardini S; Cassetta E; Rossini PM; Squitieri F; Benussi L; Binetti G
    J Alzheimers Dis; 2009; 18(2):295-303. PubMed ID: 19584443
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Longitudinal stability of CSF biomarkers in Alzheimer's disease.
    Blennow K; Zetterberg H; Minthon L; Lannfelt L; Strid S; Annas P; Basun H; Andreasen N
    Neurosci Lett; 2007 May; 419(1):18-22. PubMed ID: 17482358
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantification of amyloid-beta 40 in cerebrospinal fluid.
    Verwey NA; Veerhuis R; Twaalfhoven HA; Wouters D; Hoozemans JJ; Bollen YJ; Killestein J; Bibl M; Wiltfang J; Hack CE; Scheltens P; Blankenstein MA
    J Immunol Methods; 2009 Aug; 348(1-2):57-66. PubMed ID: 19576899
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The N-domain of angiotensin-converting enzyme specifically hydrolyzes the Arg-5-His-6 bond of Alzheimer's Abeta-(1-16) peptide and its isoAsp-7 analogue with different efficiency as evidenced by quantitative matrix-assisted laser desorption/ionization time-of-flight mass spectrometry.
    Toropygin IY; Kugaevskaya EV; Mirgorodskaya OA; Elisseeva YE; Kozmin YP; Popov IA; Nikolaev EN; Makarov AA; Kozin SA
    Rapid Commun Mass Spectrom; 2008; 22(2):231-9. PubMed ID: 18085519
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.